Search Results for “vaccine” – Page 6 – media

NIHR reveals phase 1/2 trial to evaluate an investigational vaccine for mpox in the UK

More than 3,700 cases of mpox have been identified in the UK since May 2022 The National Institute for Health and Care Research (NIHR) has announced a new phase 1/2 trial, delivered by the NIHR Clinical Research Network and sponsored by Moderna, to test the effectiveness of an investigational mRNA vaccine for mpox. The mPower trial will evaluate the safety and immune response to mRNA-1769, which aims to protect against illness caused by the mpox virus. Currently a global public health threat, mpox is an infectious disease caused by the monkeypox virus, which is spread through physical contact with someone who is infected, leading to symptoms including painful rashes, enlarged lymph nodes and fever. Since May 2022, over 3,700 cases of mpox have been identified in the UK, the majority of which have been from the Clade II B.1 lineage, predominantly in gay, bisexual and other men who have sex ...
- Source: drugdu
- 148
- March 19, 2024
NHS campaign urges over 900,000 young adults to catch up on missed MMR vaccine

The NHS has announced it is targeting young adults to catch up on their missed measles, mumps and rubella (MMR) vaccines as part of the NHS catch-up campaign. In England, more than 900,000 adults aged 19 to 25 years will be invited to book an appointment for their missed vaccine. Following on from the national health service’s recent reminder for 200,000 16- to 19-year-olds to receive the MMR vaccine, the NHS campaign will target young adults in areas more at risk: the West Midlands, Greater Manchester and London. MMR are highly infectious illnesses that can lead to blindness, deafness and swelling of the brain. Currently one of the most infectious diseases globally, with no medical treatment available, one adult or child infected with measles can pass the disease on to around 15 other unvaccinated individuals. According to the UK Health Security Agency (UKHSA), between October 2023 and March 2024, approximately ...
- Source: drugdu
- 120
- March 14, 2024
Pfizer’s Bivalent Respiratory Syncytial Virus Vaccine Shows Promising Efficacy Across Two Seasons

Davy James Abrysvo was found to produce durable efficacy against respiratory syncytial virus across two seasons in adults 60 years of age and older. Top-line data from the ongoing, pivotal Phase III RENOIR clinical trial (NCT05035212) demonstrated that Pfizer’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine Abrysvo produces durable efficacy against respiratory syncytial virus (RSV) across two seasons in adults 60 years of age and older. Efficacy against RSV-associated lower respiratory tract disease (LRTD), defined as three or more symptoms, was 88.9% after the first season, whereas efficacy was 77.8% after the second season.1 “We are encouraged by the level of protection that we observed after two full RSV seasons for Abrysvo,” Annaliesa Anderson, PhD, Pfizer senior vice president and chief scientific officer, Vaccine Research and Development, said in a press release. “This new data indicate that broad and durable protection against both types of RSV that cause ...
- Source: drugdu
- 154
- March 4, 2024
Recommendations announced for influenza vaccine composition for the 2024-2025 northern hemisphere influenza season

The World Health Organization (WHO) today announced the recommendations for the viral composition of influenza vaccines for the 2024-2025 influenza season in the northern hemisphere. The announcement was made at an information session after a 4-day meeting on the Composition of Influenza Virus Vaccines. The meeting is held twice annually, once for the southern and once for the northern hemisphere. WHO organizes these consultations with an advisory group of experts gathered from WHO Collaborating Centres and WHO Essential Regulatory Laboratories to analyse influenza virus surveillance data generated by the WHO Global Influenza Surveillance and Response System (GISRS). The recommendations issued are used by the national vaccine regulatory agencies and pharmaceutical companies to develop, produce, and license influenza vaccines for the following influenza season. The periodic update of viruses contained in influenza vaccines is necessary for the vaccines to be effective due to the constant evolving nature of influenza viruses, including ...
- Source: drugdu
- 86
- February 28, 2024
Novavax and Gavi Settle Dispute Over Covid Vaccines Pact, Avoiding Arbitration

By settling now and agreeing to deferred payments over the next five years, Novavax avoids the risk of being responsible for a much bigger payout all at once. The arbitration hearing over the disputed vaccine purchase agreement with Gavi was scheduled for this summer. By FRANK VINLUAN Novavax isn’t in a good financial position to be refunding money to customers, having gone through a cost-saving restructuring amid flagging sales of the Covid-19 vaccine that is its only revenue-generating product. But arbitration is uncertain, so rather than roll the dice and risk a huge payout if the dispute resolution does not go its way, the company has agreed to pay Gavi, the Vaccine Alliance, as much as $475 million over the next five years to settle a squabble over a $700 million purchase agreement. Like other Covid-19 vaccine makers, Gaithersburg, Maryland-based Novavax supplies its vaccine under advance purchase agreements. Government bodies ...
- Source: drugdu
- 95
- February 24, 2024
Bavarian Nordic Hones Infectious Disease Focus by Dropping Cancer Vaccine R&D

Bavarian Nordic will concentrate on its portfolio and pipeline of infectious diseases vaccines, including top seller Jynneos, approved for mpox and smallpox. The company only had one clinical-stage cancer vaccine program. By FRANK VINLUAN The mpox outbreak is a memory, but Bavarian Nordic, maker of the only FDA-approved vaccine for the pathogen behind this viral infection, turned skyrocketing demand for its product into record revenue. With that growth comes a need to focus, and the pure-play vaccines company is getting out of the business of developing vaccines for cancer. Bavarian Nordic’s lone cancer vaccine candidate, TAEK-VAC, had reached Phase 1 testing as a potential treatment for chordoma or HER2-positive breast cancer. But this program had also reached the point where further investment is needed, and Bavarian Nordic decided it needs to focus its R&D efforts on infectious disease, the Denmark-based company said Wednesday in its announcement of preliminary 2023 financial ...
- Source: drugdu
- 158
- February 23, 2024
Olymvax’s Quadrivalent Influenza Virus Vaccine (Split Virion) Clinical Trials Accepted

Recently, the State Drug Administration announced on its website that it agreed to accept Olymvax’s application to conduct clinical trials of quadrivalent influenza virus cracking vaccine, marking new progress in Olymvax’s first product pipeline of virus-based vaccines. Influenza (also known as influenza) is an acute respiratory infection caused by influenza viruses, spread by respiratory droplets and contact, and the population is generally susceptible. Influenza poses a significant burden on global public health, and vaccination is the most effective way to reduce this burden. Vaccination with quadrivalent influenza virus lysate vaccine can stimulate the body to produce anti-influenza virus immunity, and is used to prevent influenza caused by vaccine-associated types of influenza viruses. Currently, most of the influenza vaccines available in China are based on chicken embryos. The influenza vaccine developed by Olymvax is based on MDCK cell mass culture technology, which can realize higher production yield, more stable product quality ...
- Source: drugdu
- 79
- February 23, 2024
Recombinant Herpes Zoster Vaccine Independently Developed by Shanghai Institutes for Biological Products of China Receives Clinical Trial Approval Notice

On February 20, the recombinant herpes zoster vaccine, a Class I new drug independently developed by Shanghai Institutes for Biological Products of China, received a notice of approval for clinical trial from the State Drug Administration. Herpes zoster is a common viral infectious disease caused by the reactivation of varicella-zoster virus latent in the human sensory ganglia, with severe nerve pain and skin herpes as the main symptoms. According to relevant data, there are about 1.56 million new cases of herpes zoster in people aged 50 years and above every year in China. Herpes zoster and its complications seriously affect the work and life of patients. Vaccination against herpes zoster is an important measure for the prevention of herpes zoster and postherpetic neuralgia, but at present there are limited varieties of herpes zoster vaccine available in China. Shanghai Institutes for Biological Products (SIBI) has independently developed a recombinant herpes zoster ...
- Source: drugdu
- 88
- February 22, 2024
MHRA agrees licence change for Pfizer-BioNTech’s Comirnaty vaccine

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for a variation in licence for Pfizer-BioNTech’s 30 micrograms dose of Comirnaty XBB.1.5, a Covid-19 vaccine targeting the Omicron variant. The decision follows the vaccine’s fulfilment of the UK regulator’s safety, quality and effectiveness standards. The latest approval for the single-dose vials allows for the vaccine’s thawing and re-labelling by an authorised manufacturer outside of the UK’s National Health Service (NHS), adhering to good manufacturing practice standards. The NHS previously managed the thawing and distribution of the Comirnaty Omicron XBB.1.5 vaccine centrally. The vaccine requires ultra-low temperature storage at -80°C before it is thawed for usage. MHRA noted that the formulation of the Comirnaty vaccine, approved in September 2023, remains unchanged. The new authorisation by the MHRA is applicable only in Great Britain. The UK regulator also approved Novavax’s Nuvaxovid, an adapted vaccine targeting the Omicron XBB 1.5 ...
- Source: https://www.pharmaceutical-technology.com/news/mhra-licence-pfizer-biontech-vaccine/?cf-view
- 100
- February 13, 2024
SINOVAC Influenza Vaccine Exported to Chile for the First Time, Helping to Prevent and Control the 2024 Influenza Season in the Southern Hemisphere

On February 2, 2024, a batch of trivalent influenza vaccine Anflu® produced by SINOVAC arrived in Santiago, Chile. This is the first time that SINOVAC influenza vaccines have exported finished influenza vaccines prepared from the candidate strains recommended by the World Health Organization for influenza vaccines in the southern hemisphere to a country in the southern hemisphere. The vaccine will be distributed to private vaccination centers in Santiago and other major cities across the country for the local 2024 Southern Hemisphere Influenza Season vaccination campaign starting in March. Bárbara Ester Orellana Álvarez, SINOVAC’s Director of Registration in Chile, said the vaccine is now safely stored in cold storage under license from the Chilean Institute of Public Health (ISP). The timely arrival of this shipment demonstrates SINOVAC’s commitment to providing the Chilean people with vaccines of the highest quality and safety standards. “We are confident that this operation will contribute to ...
- Source: drugdu
- 85
- February 5, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.